innerbuddies gut microbiome testing

Gut Microbiome and Multiple Sclerosis: How Your Microbiota Fuels Autoimmune Inflammation

Multiple sclerosis (MS) is increasingly understood as more than a disorder of the central nervous system—it’s also shaped by the immune system’s interactions with the gut. Your gut microbiome, a vast community of microbes living in the intestines, can influence how immune responses are “trained” and regulated. Through the gut–immune and gut–brain connections, microbial signals can affect inflammation, immune cell behavior, and even pathways involved in nerve health.

Research over the past decade suggests that people with MS often show distinct gut microbial patterns compared with people without MS. These differences can include changes in diversity and shifts in specific bacterial groups that are linked to either pro-inflammatory or protective immune signaling. Certain microbes (and the compounds they produce—like short-chain fatty acids and other metabolites) may help maintain intestinal barrier function and encourage regulatory immune pathways, while others may promote immune activation and autoimmune inflammation in susceptible individuals.

The promising takeaway is that gut health may be a modifiable factor in MS biology. By supporting a microbiome that produces beneficial metabolites and reinforces a healthy gut barrier, you may help create a more balanced immune environment. In this guide, we’ll explore the microbiota–gut–brain links, the key bacterial changes observed in MS research, and practical, evidence-informed strategies to support gut microbiome resilience as part of an overall MS wellness approach.

Get Your Gut Microbiome MS Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Multiple sclerosis

Microbiome testing, including the InnerBuddies approach described, aims to identify an individual’s gut ecosystem patterns linked to inflammatory risk, assess barrier integrity and SCFA potential, and guide personalized dietary and lifestyle adjustments. By tailoring fiber intake, plant diversity, and suitable prebiotic/probiotic options to a person’s baseline microbiome and tracking changes over time, testing strives to reduce inflammatory drivers and support symptom-relevant gut–immune pathways, offering a more targeted approach to MS management rather than generic recommendations.

  • Scarcity of SCFA-producing gut microbes (Faecalibacterium prausnitzii, Roseburia, Ruminococcus, Coprococcus) reduces butyrate production and gut barrier support, potentially fueling MS inflammation.
  • Low levels of Bifidobacterium spp. may diminish anti-inflammatory signaling and regulatory T cell support; strategies to boost Bifidobacterium with fiber-rich diets or targeted prebiotics.
  • Rise of Enterobacteriaceae (e.g., E. coli, Klebsiella) in MS-associated dysbiosis correlates with increased gut permeability and pro-inflammatory immune activation.
  • Expansion of pro-inflammatory taxa such as Prevotella, Bacteroides, Sutterella, and Rikenellaceae may tilt immune balance toward inflammation via the microbiota–gut–brain axis.
  • Akkermansia muciniphila shows mixed patterns in MS (often reduced with barrier impairment, but sometimes elevated); interpretation should be individualized to barrier health.
  • Reduced overall microbial diversity and loss of beneficial taxa limit SCFA production and anti-inflammatory signaling, potentially worsening neuroinflammation.
  • Diet- and lifestyle-driven microbiome diversification (e.g., high-fiber, plant-forward patterns) aims to boost SCFA producers and regulatory pathways, potentially tempering MS inflammatory pressure.
Get Your Gut Microbiome MS Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Autoimmune disease

Multiple sclerosis (MS) is a chronic autoimmune disease in which immune cells mistakenly target the central nervous system—especially the brain and spinal cord—leading to inflammation, demyelination, and progressive neurologic symptoms. While genetics and environmental factors contribute, growing evidence shows that the gut microbiome—trillions of microbes living in the intestines—can meaningfully shape immune responses. This has fueled interest in the microbiota–gut–brain axis, a bidirectional communication network linking gut microbes, intestinal barrier function, immune signaling, and inflammation in the nervous system.

Research suggests that MS patients often show distinct gut microbial patterns compared with healthy individuals, including reduced beneficial diversity and shifts in specific bacterial groups. These microbial changes may influence disease by affecting the balance between pro-inflammatory and anti-inflammatory immune pathways, altering regulatory T-cell function, and producing metabolites such as short-chain fatty acids (SCFAs) that support gut barrier integrity. When the intestinal barrier becomes more permeable (“leaky gut” concept), bacterial components and inflammatory signals may cross more easily into systemic circulation, potentially amplifying immune activation that can exacerbate autoimmune inflammation.

The promising takeaway is that gut microbiome modulation may help support MS outcomes by reducing inflammatory pressure and strengthening gut health. Approaches often discussed in the research include diet patterns that promote microbial diversity (e.g., high-fiber, plant-forward intake), targeted prebiotics/probiotics where appropriate, and lifestyle factors that influence microbial ecology such as regular physical activity and adequate sleep. Importantly, responses can be individualized—so the goal is not a one-size-fits-all supplement, but evidence-informed strategies that support a resilient, metabolically active microbiome that may help temper inflammation relevant to MS.

  • Fatigue (often persistent and worsening over time)
  • Numbness or tingling (paresthesias)
  • Muscle weakness and spasticity
  • Balance and coordination problems (dizziness, gait instability)
  • Vision problems (e.g., optic neuritis, blurred or reduced vision)
  • Cognitive difficulties (slowed thinking, memory or attention issues)
  • Bowel and bladder dysfunction (constipation, urgency, urinary frequency)
Get Your Gut Microbiome MS Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Multiple sclerosis

This information is most relevant for people living with multiple sclerosis (MS)—including those recently diagnosed, as well as those with long-standing disease—especially when fatigue, numbness/tingling, muscle weakness or spasticity, and balance problems are significantly affecting day-to-day life. Because MS involves immune-driven inflammation in the central nervous system, readers who are also noticing gut-related changes (like constipation, urgency, or urinary frequency) may find the microbiota–gut–brain connection particularly relevant, as gut health can influence immune signaling and inflammatory tone that may affect neurological symptoms.

It’s also a good fit for individuals who want to understand “why gut health matters” in MS and are interested in practical, evidence-informed ways to support intestinal barrier function and immune regulation. This includes people who suspect their diet, stress, disrupted sleep, or low fiber intake may be shaping their gut microbiome toward a more pro-inflammatory profile—potentially through reduced microbial diversity, altered gut bacteria composition, or lower production of beneficial metabolites such as short-chain fatty acids (SCFAs) that help maintain gut integrity.

Additionally, this content is relevant for readers seeking personalized, non–one-size-fits-all strategies to complement standard MS care. If you’re looking for options like plant-forward, high-fiber dietary patterns; appropriately targeted prebiotics/probiotics; and lifestyle habits (regular physical activity, adequate sleep, and stress management) that may help foster a resilient microbiome, this approach can align well with symptoms such as cognitive changes, vision disturbances, and ongoing inflammation-related fatigue. It’s especially relevant for those who want to discuss gut-focused interventions with their clinician to ensure safety and fit with their MS treatment plan.

Multiple sclerosis (MS) affects about 2.8 million people worldwide, with prevalence highest in parts of North America, Europe, and Australasia. In the United States, estimates commonly place MS at roughly 1.0 million affected individuals, and in many European countries prevalence is on the order of ~100–200 cases per 100,000 people (varies by region and study methods). MS often begins in young to middle adulthood (commonly between ages 20–40), which helps explain why symptoms such as fatigue, numbness/tingling, vision changes, and mobility problems can significantly disrupt quality of life during working years.

Symptom burden is a major driver of healthcare utilization in MS. Fatigue is reported by many patients as one of the most common and often most persistent symptoms, and neurologic complaints such as sensory disturbances (paresthesias), muscle weakness and spasticity, and balance/coordination difficulties are also frequently seen across disease stages. Vision problems—especially optic neuritis—are a classic presenting feature for many people, while cognitive difficulties (attention, processing speed, memory) and bowel/bladder dysfunction (constipation, urgency, urinary frequency) commonly emerge as the disease progresses or during relapses.

Because MS has an immune-mediated course with variable presentation, prevalence statistics don’t always reflect how widespread each symptom feels day-to-day. However, real-world cohorts and clinical studies consistently show that fatigue and sensory or motor symptoms are among the most frequent complaints, with vision and bladder/bowel problems also occurring in a substantial subset of patients over time. While microbiome-related research is still evolving, the same factors that influence immune regulation—such as inflammation, gut barrier integrity, and metabolite signaling along the gut–brain axis—are being explored as potential contributors to symptom patterns, making microbiome-centered prevention and supportive strategies of growing interest.

Get Your Gut Microbiome MS Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome & Multiple Sclerosis: How Your Microbiota Impacts Autoimmune Inflammation

Multiple sclerosis (MS) is an autoimmune disease where immune activity damages the central nervous system, but research increasingly suggests that the gut microbiome may influence that immune misfiring. The trillions of microbes in the intestines help shape immune balance by interacting with gut-associated immune cells, supporting regulatory pathways (including regulatory T cells) that normally keep inflammation in check. In many studies, people with MS show differences in gut microbial composition compared with healthy controls—often characterized by reduced beneficial diversity and shifts in specific bacterial groups that can tilt the immune system toward a more inflammatory state.

A key mechanism connecting the gut and MS is the microbiota–gut–brain axis, which involves immune signaling, intestinal barrier function, and microbial metabolites. When the intestinal barrier becomes more permeable, bacterial components and inflammatory signals may cross more easily into circulation, potentially amplifying systemic immune activation that can worsen neuroinflammation. At the same time, gut microbes produce metabolites such as short-chain fatty acids (SCFAs) that help maintain gut barrier integrity and promote anti-inflammatory immune responses. If microbial patterns shift away from SCFA-producing communities, both barrier health and immune regulation may be affected, potentially contributing to MS disease activity.

These gut-related immune effects may help explain why MS symptoms often overlap with pathways influenced by microbiome health, including fatigue, sensory disturbances, muscle spasticity, and vision or cognitive changes that reflect ongoing inflammation and neurologic injury. Bowel and bladder dysfunction is also common in MS, and gut dysbiosis and altered gut barrier function may influence gastrointestinal motility and immune signaling. The promising takeaway is that microbiome-targeted lifestyle and dietary strategies—such as a high-fiber, plant-forward diet to support microbial diversity, and individualized use of prebiotics/probiotics where appropriate—may help reduce inflammatory pressure and support more resilient immune balance in MS.

Get Your Gut Microbiome MS Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and Multiple sclerosis

  • Microbiota-driven immune skewing: MS-associated shifts in gut microbial composition can alter immune balance by reducing regulatory pathways (e.g., regulatory T cells) and promoting pro-inflammatory responses (including Th17 responses).
  • Disrupted intestinal barrier (leaky gut) and systemic immune activation: Gut dysbiosis may impair tight-junction integrity, increasing intestinal permeability so microbial components and inflammatory signals cross into circulation and amplify neuroinflammation.
  • Microbial metabolite signaling (SCFAs and other metabolites): Changes in SCFA-producing bacteria can reduce anti-inflammatory metabolites that normally support immune regulation and barrier maintenance, potentially worsening MS disease activity.
  • Microbiota–gut–brain axis via neuroimmune signaling: Gut immune and inflammatory signals (cytokines, chemokines, microbial products) can influence CNS immune activity through neural, endocrine, and immune pathways, affecting demyelination and neuronal injury.
  • Patterned antigen exposure and molecular mimicry: Certain microbial antigens may prime or cross-react with immune targets relevant to MS, enhancing autoreactive immune responses in the CNS.
  • Altered bile acid metabolism and signaling: Gut microbes transform bile acids into immunomodulatory compounds; dysregulation of this pathway can affect inflammation and T-cell function relevant to MS.
  • Gut motility and downstream inflammation (gut–brain symptom overlap): MS-related bowel dysfunction and microbiome alterations can reinforce inflammatory signaling through changes in motility, nutrient availability, and microbiome ecology, contributing to fatigue and sensory/cognitive symptoms.

Multiple sclerosis (MS) involves misdirected immune activity in the central nervous system, and the gut microbiome appears to help shape how well immune responses are regulated. In people with MS, studies often find differences in gut microbial composition that can reduce “beneficial” diversity and shift immune balance away from anti-inflammatory pathways. Mechanistically, this can influence regulatory T cells and promote pro-inflammatory immune programs such as Th17 responses, creating a systemic inflammatory environment that can support neuroinflammation.

Another key connection is the microbiota-driven intestinal barrier. When gut dysbiosis disrupts tight junctions and increases intestinal permeability, bacterial components and inflammatory signals can cross more easily into circulation. This may amplify systemic immune activation and feed into the neuroimmune processes that contribute to demyelination and neuronal injury. At the same time, gut microbes produce metabolites—especially short-chain fatty acids (SCFAs)—that normally help maintain barrier integrity and support anti-inflammatory immune signaling. If SCFA-producing communities decline, both barrier health and immune restraint may weaken, potentially worsening MS activity.

These effects converge through the microbiota–gut–brain axis, where immune and metabolic signals communicate with the CNS via neuroimmune, endocrine, and immune pathways. Gut-derived cytokines, chemokines, and microbial products can affect CNS immune behavior, while altered microbial metabolites such as bile-acid derivatives can modulate T-cell function. Additionally, patterned exposure to certain microbial antigens may contribute to immune cross-reactivity, and changes in gut motility can reinforce inflammation and symptom overlap (e.g., fatigue, sensory changes, and cognitive issues) by altering nutrient availability and the gut ecosystem.

Get Your Gut Microbiome MS Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Microbial patterns summary

In multiple sclerosis (MS), researchers commonly report a gut microbiome that differs from that of healthy controls, often showing reduced overall microbial diversity and shifts in the relative abundance of specific bacterial groups. Patterns frequently described include a move away from communities thought to support immune tolerance and toward taxa associated with more pro-inflammatory immune signaling. These compositional differences are relevant because gut microbes shape the balance between regulatory pathways (including regulatory T cells) and inflammatory programs such as Th17 responses, which can influence systemic immune tone that may feed into neuroinflammation.

A recurring theme is altered microbial function rather than only changes in which organisms are present. Many studies link MS-associated dysbiosis to lower capacity for producing short-chain fatty acids (SCFAs)—key metabolites that help reinforce intestinal barrier integrity and promote anti-inflammatory immune effects. When SCFA-producing communities decline, the gut lining may become less well protected, allowing microbial products and inflammatory signals to cross more readily into circulation. This “leaky gut” tendency can amplify immune activation systemically, creating conditions that may worsen inflammatory processes in the central nervous system.

These changes converge through the microbiota–gut–brain axis, where immune and metabolic signals travel between the intestine and the CNS. Dysbiosis can alter intestinal permeability, cytokine signaling, and metabolite profiles (including SCFAs and other gut-derived compounds such as bile-acid derivatives), which can affect how T cells behave and how immune cells are recruited or restrained. Over time, immune dysregulation plus shifting microbial metabolite inputs may contribute to the symptom overlap often seen in MS—such as fatigue, sensory disturbances, spasticity, and cognitive or vision changes—by sustaining an inflammatory milieu and influencing neuroimmune communication.


Low beneficial taxa

  • Faecalibacterium prausnitzii (SCFA/anti-inflammatory producer; often reduced in MS)
  • Roseburia spp. (butyrate-producing; often reduced)
  • Ruminococcus spp. (particularly SCFA-supporting lineages; often reduced)
  • Akkermansia muciniphila (mucin/intestinal barrier–supporting; frequently reported reduced in dysbiosis)
  • Bifidobacterium spp. (immunomodulatory; often reduced in MS cohorts)
  • Coprococcus comes (butyrate producer; often reduced)


Elevated / overrepresented taxa

  • Akkermansia muciniphila
  • Enterobacteriaceae (family; e.g., Escherichia coli, Klebsiella spp.)
  • Prevotella spp.
  • Bacteroides spp.
  • Sutterella spp.
  • Rikenellaceae (family)


Functional pathways involved

  • Short-chain fatty acid (SCFA) biosynthesis (butyrate/propionate/acetate) and SCFA-mediated Treg/anti-inflammatory signaling
  • Bile acid metabolism and bile-acid derivative signaling (e.g., FXR/TGR5-related immune modulation)
  • Intestinal barrier integrity pathways (mucin degradation/production balance, mucus layer maintenance, tight-junction function) and permeability regulation
  • Microbial lipopolysaccharide (LPS) and other endotoxin biosynthesis/processing leading to Toll-like receptor (TLR)–driven pro-inflammatory immune activation
  • Microbial amino acid metabolism and tryptophan/indole derivatives affecting aryl hydrocarbon receptor (AhR) and Th17 vs Treg immune balance
  • Prevotella/Bacteroides-associated carbohydrate fermentation and dietary fiber utilization affecting community metabolism and immune tone
  • Inflammatory metabolite production (e.g., branched-chain amino acid and other pro-inflammatory metabolite pathways) that can sustain systemic immune activation


Diversity note

In people with multiple sclerosis (MS), studies commonly find that the gut microbiome is less diverse than in healthy controls, with shifts in the relative abundance of specific bacterial groups. This reduction in overall diversity often accompanies a move away from microbes and functional pathways associated with immune regulation and toward profiles that correlate with a more pro-inflammatory immune tone. Because gut microbes help train and balance immune responses—especially regulatory pathways such as regulatory T cells—these diversity changes can be relevant to the immune misfiring that characterizes MS.

Beyond who is present, MS-associated alterations frequently involve microbial function. A recurring finding is a diminished capacity for producing short-chain fatty acids (SCFAs), metabolites that support intestinal barrier integrity and help drive anti-inflammatory immune signaling. When SCFA-producing communities decline, the intestinal lining may become less protected, which can increase intestinal permeability and allow microbial products and inflammatory cues to interact more strongly with the immune system.

These diversity- and function-related shifts connect to MS through the microbiota–gut–brain axis, where gut-derived signals influence immune activity that can affect the central nervous system. Altered microbial communities can change metabolite availability (including SCFAs and other gut-derived compounds), influence cytokine signaling, and affect how immune cells are recruited or restrained. Over time, this can sustain a more inflammatory systemic environment, helping explain why MS symptoms often align with pathways influenced by gut microbiome health, such as fatigue, sensory changes, spasticity, and cognitive or vision disturbances.


Get Your Gut Microbiome MS Test Get Your Gut Microbiome Test Subscription

Why generic solutions fail

  • Issue with generic solutions

    For multiple sclerosis, generic “one-size-fits-all” gut interventions often underperform because MS gut dysbiosis isn’t just about having more or less of a few bacteria—it’s about differences in microbial function, such as reduced short-chain fatty acid (SCFA) production and altered immune-regulatory signaling. Many broad approaches (e.g., generic probiotic blends or standard advice to “eat healthier”) may not reliably restore SCFA-producing community capacity, intestinal barrier resilience, or the balance between regulatory T-cell pathways and pro-inflammatory programs like Th17-driven responses. Without targeting the functional deficits that influence immune tone, symptom-related improvements are inconsistent and often temporary.

    Generic dietary guidance can also fail because MS patients vary widely in baseline diet pattern, fiber tolerance, comorbid gastrointestinal symptoms (constipation, diarrhea, bloating), medication exposures (including disease-modifying therapies and antibiotics), and microbiome baseline composition. High-fiber recommendations without accounting for fermentation sensitivity or GI motility differences can worsen tolerability, leading to reduced adherence and less microbiome “re-shaping” over time. Likewise, probiotics that are effective in one microbiome context may not engraft or may not meaningfully change metabolite outputs (SCFAs, bile-acid derivatives) in another.

    Finally, many interventions ignore the microbiota–gut–brain axis timing and feedback loop—where changes in barrier permeability, immune activation, and gut-derived metabolites can influence neuroinflammation and neurologic symptoms. Generic protocols rarely account for whether a person’s gut barrier is functionally compromised, whether immune activation markers are trending down, or whether metabolite signatures are shifting toward anti-inflammatory profiles. In MS, where immune misfiring is dynamic, strategies need to be individualized and monitored for functional readouts; otherwise, the intervention may not meaningfully dampen systemic inflammatory pressure that can feed central nervous system activity.

  • Common mistakes

    • Treating MS gut dysbiosis as a “who’s there” problem rather than targeting functional deficits (e.g., reduced short-chain fatty acid [SCFA] production and altered immune-regulatory metabolite output).
    • Using generic probiotic blends without matching to the person’s baseline microbiome context, which can lead to poor engraftment and minimal changes in metabolite signals (SCFAs, bile-acid derivatives) that influence immune tone.
    • Prescribing high-fiber plans without accounting for fermentation sensitivity, constipation/diarrhea patterns, GI motility differences, or existing symptoms (bloating, intolerance), reducing adherence and disrupting microbiome remodeling.
    • Overlooking medication and exposure effects (especially antibiotics and disease-modifying therapies) that can shift microbiome composition and function, making one-size protocols unreliable.
    • Ignoring intestinal barrier/function status (permeability, inflammation markers) and assuming symptom improvement will occur without addressing the leaky-gut–driven immune activation loop.
    • Failing to individualize based on microbiota–gut–brain axis dynamics (timing and feedback loops), so interventions don’t meaningfully dampen systemic inflammatory pressure that can feed CNS neuroinflammation.
    • Focusing on broad “healthy diet” advice without functional readouts (diet tolerance, stool pattern, SCFA-related markers), leading to inconsistent and temporary outcomes.
    • Not accounting for inter-individual variability in baseline diet pattern and nutrient intake, which can prevent the intended substrate from reaching the microbes responsible for anti-inflammatory metabolites.

What to do

  • General support strategies

    In multiple sclerosis, the gut microbiome may help set the tone for immune balance, in part through immune cells located in the gut and through microbial metabolites that influence inflammation. General support strategies often focus on nurturing microbial diversity and promoting anti-inflammatory signaling pathways. A high-fiber, plant-forward pattern—emphasizing a variety of vegetables, legumes, whole grains, nuts, seeds, and other minimally processed foods—helps feed beneficial gut microbes that produce short-chain fatty acids (SCFAs). These SCFAs support intestinal barrier integrity and help encourage regulatory immune responses (including regulatory T cells) that normally keep inflammation in check.

    Because intestinal barrier health and the microbiota–gut–brain axis are increasingly discussed in MS, strategies that reduce inflammatory pressure in the gut may be particularly relevant. Many people benefit from minimizing gut-irritating dietary patterns (such as highly processed, low-fiber diets and excess added sugars), while prioritizing foods that support a stable barrier and a favorable microbial ecosystem. Hydration, adequate sleep, and stress-management practices may also matter indirectly by shaping gut motility, microbial function, and immune signaling—factors that can influence common MS-related issues like fatigue and gastrointestinal discomfort.

    Some individuals also explore microbiome-targeted supplements and adjuncts, such as prebiotic fibers (e.g., inulin-type fibers, resistant starch, or other fermentable fibers) or probiotics/“synbiotics,” aiming to enhance beneficial taxa and metabolic outputs. The most appropriate approach is often individualized, since MS symptoms and tolerability vary, and certain products may not be suitable for everyone. Taken together, the overall goal is to support a healthier gut ecosystem, strengthen barrier function, and foster immune regulation that may help complement standard MS care.

  • Lifestyle recommendations

    • Adopt a high-fiber, plant-forward diet (varied vegetables, legumes, whole grains, nuts/seeds) to support beneficial gut diversity and short-chain fatty acid (SCFA) production.
    • Increase intake of prebiotic foods (e.g., garlic, onions, leeks, asparagus, bananas/plantains, oats, beans) regularly to feed SCFA-producing microbes.
    • Consider food-based fermented products (e.g., yogurt with live cultures, kefir, sauerkraut, kimchi) and/or discuss evidence-based probiotic use with a clinician, especially if you have GI symptoms.
    • Support gut barrier and reduce inflammatory signaling by limiting ultra-processed foods, added sugars, and excessive saturated/trans fats.
    • Maintain a healthy body weight and prioritize regular physical activity within your ability, as exercise is associated with more favorable microbiome profiles and immune regulation.
    • Avoid unnecessary antibiotics and smoking; discuss any required antibiotics or treatments with your clinician and consider gut-supportive nutrition during/after courses.

  • Nutrition recommendations

    • Follow a high-fiber, plant-forward diet (aim for diverse vegetables, legumes, whole grains, nuts, and seeds) to support beneficial microbial diversity and SCFA production.
    • Prioritize prebiotic foods that feed helpful gut bacteria—examples include onions, garlic, leeks, asparagus, oats, green bananas, and legumes—and increase gradually to reduce GI discomfort.
    • Include fermentation-friendly options (e.g., yogurt/kefir with live cultures, sauerkraut, kimchi) if tolerated, to potentially support a healthier microbiome—choose low-sugar versions.
    • Limit ultra-processed foods, added sugars, and high saturated-fat diets, which are associated with less favorable microbial profiles and higher inflammatory signaling.
    • Support intestinal barrier function by ensuring adequate protein and micronutrients (e.g., omega-3 fats from fatty fish or algae, vitamins A/D/E, zinc, magnesium) through whole-food sources.
    • If constipation or diarrhea is present, tailor fiber type and intake (soluble fibers like oats/chia often help with stool consistency; consider a structured trial rather than large swings).
    • Discuss individualized probiotic or prebiotic supplementation with a clinician, especially if you have active GI symptoms or are considering changes alongside MS therapies.

  • Supplement considerations

    In multiple sclerosis (MS), supplement discussions increasingly focus on supporting a gut environment that promotes immune tolerance rather than inflammation. Because gut microbes help train and regulate immune pathways—including regulatory T cells—nutrients that encourage microbial diversity and beneficial taxa may be relevant. In practice, this often means emphasizing fiber-first approaches (which can be supported with prebiotic fibers) and considering targeted probiotic or postbiotic options in selected people, with attention to strain-specific evidence and individual tolerance. Since MS is associated with gut dysbiosis in many studies, supplement strategies are generally framed as “immune-support through the microbiome,” aiming to reduce inflammatory signaling that could otherwise intensify neuroinflammation.

    A second consideration is intestinal barrier function and microbial metabolites. Supplements that increase short-chain fatty acid (SCFA) availability or mimic SCFA effects (for example, via fermentable fibers or specific metabolite-oriented formulations) may help maintain mucosal integrity and support anti-inflammatory immune responses. Improving barrier resilience may, in theory, reduce the likelihood that microbial components or inflammatory mediators cross more easily into circulation and amplify systemic immune activation. Because bowel and bladder dysfunction are common in MS, GI-focused support—such as gut-friendly fiber types and carefully selected microbial products—may also help address constipation, bloating, or irregular motility that can further influence inflammation.

    Finally, MS care is individualized and supplements should be evaluated alongside medications and overall disease status. People with MS often take immunomodulatory therapies, so any microbiome-targeted supplement should be considered for safety (e.g., probiotic appropriateness in the setting of significant immunosuppression), potential side effects (gas/bloating from prebiotics), and interactions with diet and gut symptoms. A reasonable approach is to start conservatively, choose well-characterized products (with strain IDs where relevant), and monitor for tolerability while emphasizing sustainable dietary patterns that support microbial resilience.

  • Retesting / monitoring note

    For multiple sclerosis, microbiome-focused retesting can be most informative when it’s timed to meaningful changes in your gut ecology or symptoms—typically after an intervention period rather than immediately after starting. A common approach is to retest stool-based microbiome profiles about 8–12 weeks after dietary changes (e.g., increasing fiber and plant diversity) or after initiating a targeted prebiotic/probiotic strategy, since microbial communities and the downstream metabolites they produce (including short-chain fatty acids) usually shift on that timescale. Retesting can also be timed around periods of relative clinical stability to better interpret whether changes in microbial diversity, community balance, or metabolite-linked markers align with reduced inflammatory signals.

    Because MS is influenced by the microbiota–gut–brain axis, retesting should ideally include contextual factors that can strongly affect results, such as recent antibiotic or steroid use, constipation/diarrhea patterns, adherence to fiber targets, and any relapse or infection. If possible, standardize sample collection (e.g., consistent stool collection method and storage conditions) and document gastrointestinal symptoms and medication timing so that observed differences are more likely related to gut ecology rather than sampling variability. For many people, comparing a baseline to at least one follow-up—rather than frequent short-interval repeats—provides a more clinically meaningful readout.

    If retesting suggests limited improvement (for example, persistently low beneficial diversity or reduced signatures of SCFA-producing taxa), the next round should focus on refining the strategy—often by adjusting fiber type (soluble vs. fermentable fibers), targeting specific prebiotic ingredients, or re-evaluating probiotic selection based on tolerance and symptom response. Retesting can then be repeated another 8–12 weeks after the new plan. While the microbiome data can guide personalization, it’s also important to coordinate with MS clinicians and avoid assuming microbiome changes alone predict disease course; interpret results as part of a broader picture that includes immune status, gut barrier health proxies, and symptom tracking.

The importance of gut microbiome testing

  • Why testing matters

    Gut microbiome testing matters in multiple sclerosis because it can help clarify whether an individual’s gut ecosystem is trending toward a pattern associated with immune dysregulation. Since the microbiome communicates with the immune system through gut-associated immune cells—supporting regulatory pathways like regulatory T cells—differences in microbial diversity and key bacterial groups may help explain why some people experience higher inflammatory “pressure” that can contribute to neuroinflammation. Identifying such shifts can move discussions beyond generic wellness advice and toward a more targeted, evidence-aligned approach.

    Testing can also provide actionable insight into microbiota–gut–brain axis factors that are relevant to MS, including intestinal barrier integrity and microbial metabolite output. Microbial communities influence whether the gut produces beneficial metabolites such as short-chain fatty acids (SCFAs), which help maintain barrier function and promote anti-inflammatory signaling. When testing reveals lower SCFA-associated potential or signs consistent with barrier-stress patterns, it may support selecting dietary and lifestyle interventions aimed at restoring microbial metabolites and improving immune balance.

    Finally, microbiome testing can help personalize nutrition and supplementation strategies that are often proposed for MS, such as increasing fiber and plant diversity, and considering prebiotic or probiotic options tailored to the person’s baseline microbiome. Because microbiome composition varies widely between individuals, the “same” intervention can produce different outcomes. By tracking an individual’s starting microbial profile (and ideally changes over time), testing can improve the likelihood of choosing strategies that best reduce inflammatory drivers and support symptom-relevant gut and immune pathways.

  • How InnerBuddies helps

    InnerBuddies microbiome testing can help people with multiple sclerosis better understand how their gut ecosystem may be influencing immune balance through the microbiota–gut–brain axis. Because MS is associated with immune dysregulation, the test looks for patterns in gut microbial composition and diversity that have been linked in research to a more inflammatory immune “set point,” including shifts away from beneficial, regulatory-supporting microbes. This can give context for why some individuals experience higher inflammatory burden and symptom overlap (such as fatigue, sensory changes, and neurologic discomfort) that often reflects ongoing immune activity.

    By revealing microbiome features connected to gut barrier integrity and microbial metabolite potential—especially those related to short-chain fatty acid (SCFA) production—InnerBuddies may help identify whether your gut environment is trending toward reduced anti-inflammatory signaling. Since SCFAs support barrier function and promote regulatory pathways (including regulatory T cells), test insights can guide more targeted dietary and lifestyle choices aimed at restoring a healthier microbial metabolic profile. In turn, improving barrier resilience may help reduce the likelihood of inflammatory signals crossing more readily into circulation and amplifying neuroinflammation.

    Importantly, InnerBuddies supports personalization. Instead of relying on generic recommendations, the test can help tailor fiber and plant-forward strategies, as well as prebiotic or probiotic approaches, to your baseline microbiome—recognizing that people can respond differently to the same intervention. With a starting profile in hand (and ideally follow-up tracking over time), you can work toward more evidence-aligned adjustments designed to reduce inflammatory drivers and support symptom-relevant gut–immune pathways.

Medical Evidence

  • Scientific evidence level

    2 [Weak: emerging but inconsistent; stronger mechanistic rationale than clinical translation]

  • Clinical relevance note

    Current clinical relevance is limited. Gut microbiome differences in MS are sufficiently consistent at a high level (broad dysbiosis signals and immune/metabolite pathway plausibility) that they are scientifically interesting, but they are not yet reproducible enough or validated enough to guide diagnosis, risk stratification, treatment selection, or monitoring. The strongest present use is research stratification—hypothesis generation and mechanistic exploration—rather than patient-facing decision-making.

    From an evidence-based medicine standpoint, the main barrier is translation: (1) observational associations are confounded and sometimes reflect treatment, diet, geography, and disease state (reverse causality), (2) longitudinal prediction is not yet reliably demonstrated across cohorts, (3) intervention trials have not consistently shown clinically meaningful benefits with robust microbiome–outcome linkage, and (4) microbiome biomarkers lack external validation and standardization (batch effects and methodological variability). Until well-powered, multi-center longitudinal studies and rigorously designed RCTs with clinically meaningful endpoints confirm causal effects and reproducible signatures, the gut microbiome should be considered an emerging research target rather than a validated clinical tool for multiple sclerosis.

Title Journal Year Link
Fecal microbiota transplantation improves inflammation and neurologic function in multiple sclerosis models Cell Host & Microbe 2020 View →
Gut microbiome and multiple sclerosis: an overview of the evidence and potential mechanisms F1000Research 2019 View →
The gut microbiome in multiple sclerosis patients and their healthy relatives Nature Communications 2013 View →
Induction of experimental autoimmune encephalomyelitis by the gut microbiota Nature Immunology 2011 View →
Microbiome science in multiple sclerosis: a role for gut bacteria in the pathogenesis of disease Nature Immunology 2011 View →

Frequently Asked Questions

    ¿Qué es el microbioma intestinal y cómo podría relacionarse con la EM?
    El microbioma intestinal es la comunidad de microorganismos que viven en el intestino. Algunas investigaciones sugeren que los microbios intestinales pueden influir en las respuestas inmunitarias y la inflamación, lo que podría interactuar con la actividad de la EM. Es un tema en curso y no es un factor diagnóstico.
    ¿Qué es el eje microbiota–intestino–cerebro?
    Es una red de comunicación bidireccional que conecta los microbios del intestino, la barrera intestinal, el sistema inmunitario y el cerebro, involucrando señales y metabolitos. Puede influir en la salud del sistema nervioso, incluida la EM, pero los detalles aún se estudian.
    ¿Qué significa 'intestino permeable' y cómo podría afectar a la EM?
    Un intestino permeable se refiere a una mayor permeabilidad de la barrera intestinal, lo que podría permitir que sustancias bacterianas y señales inflamatorias entren en la circulación. Esto podría ampliar la activación inmunitaria sistémica y la neuroinflamación, aunque la evidencia está evolucionando.
    ¿Los microbios intestinales influyen en síntomas de la EM como la fatiga o el entumecimiento?
    Existen asociaciones entre patrones del microbioma y la regulación inmunitaria que podrían relacionarse con los síntomas, pero el microbioma no es diagnóstico y los síntomas tienen múltiples causas.
    ¿Qué patrones dietéticos podrían apoyar un microbioma más saludable en la EM?
    Las dietas ricas en plantas y fibra, con una amplia variedad de alimentos, pueden apoyar la diversidad microbiana y los metabolitos beneficiosos; las respuestas varían entre individuos.
    ¿Qué son los ácidos grasos de cadena corta (SCFA) y por qué son importantes en la EM?
    Los SCFA son metabolitos producidos por bacterias intestinales que ayudan a mantener la integridad de la barrera intestinal y a modular las respuestas inmunitarias. Son de interés en la investigación de la EM, especialmente cuando la producción de SCFA es reducida.
    ¿En qué consiste la prueba del microbioma y qué puede indicar?
    Por lo general, se utiliza una muestra de heces para perfilar los microbios intestinales y sus funciones potenciales. Los resultados pueden guiar discusiones sobre dieta y estilo de vida, pero no constituyen un diagnóstico.
    ¿Las pruebas del microbioma como InnerBuddies son diagnósticas o informativas?
    Generalmente son informativas y están diseñadas para apoyar decisiones personalizadas sobre dieta y estilo de vida; no sustituyen una diagnóstico de EM ni la medición de la actividad de la enfermedad.
    ¿Cómo interpretar los resultados? ¿Qué indicaría un patrón más inflamatorio?
    Busque menor diversidad, menos bacterias productoras de SCFA y mayor abundancia de taxa asociados con la inflamación. Discuta los resultados con un clínico o profesional de la nutrición; los hallazgos no son definitivos.
    Si la prueba muestra menor potencial de SCFA, ¿qué cambios en el estilo de vida podrían ayudar?
    Incrementar la ingesta de fibra y la diversidad de plantas para apoyar los microbios que producen SCFA, y considerar opciones prebióticas/probioticas personalizadas con la guía de un profesional.
    ¿Pueden ser útiles los probióticos o prebióticos para la EM, y cómo hablarlo con un profesional?
    Algunas personas pueden beneficiarse de opciones específicas de prebióticos o probióticos; hable con su neurólogo o gastroenterólogo para asegurar la seguridad y la compatibilidad con su tratamiento.
    ¿Con qué frecuencia debe repetirse la prueba del microbioma para seguir cambios?
    La frecuencia es individual; algunas personas realizan una prueba base y luego repiten tras varios meses cuando se realizan cambios en la dieta o el estilo de vida. Siga las indicaciones de su médico.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -